Celsius Therapeutics is a pioneering company based in Cambridge, MA, dedicated to advancing precision medicine in the field of inflammatory disease. By utilizing cutting-edge technologies such as single-cell RNA sequencing and machine learning, they aim to gain a deeper understanding of cellular programs associated with complex diseases, leading to the development of novel precision therapies.
With their SCOPE platform, Celsius Therapeutics has the ability to analyze cells in specific therapeutic settings, generating unmatched insights into disease biology. Their first therapeutic candidate, an anti-TREM1 antibody for the treatment of inflammatory bowel disease (IBD), was identified through machine learning-enabled analysis of clinical samples, showcasing their commitment to revolutionizing the treatment of immuno-inflammatory diseases.
Generated from the website